Theravance Biopharma, Inc. (TBPH) Downgraded by BidaskClub
Theravance Biopharma, Inc. (NASDAQ:TBPH) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Sunday.
TBPH has been the subject of a number of other reports. Needham & Company LLC upped their price target on shares of Theravance Biopharma from $40.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, May 11th. Leerink Swann set a $47.00 price target on shares of Theravance Biopharma and gave the company a “buy” rating in a report on Wednesday, May 10th. Piper Jaffray Companies restated an “overweight” rating and set a $42.00 price target on shares of Theravance Biopharma in a report on Wednesday, March 22nd. ValuEngine upgraded shares of Theravance Biopharma from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Finally, Cantor Fitzgerald began coverage on shares of Theravance Biopharma in a report on Friday, June 16th. They set an “overweight” rating and a $55.00 price target for the company. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $41.13.
Shares of Theravance Biopharma (NASDAQ:TBPH) traded down 4.72% during mid-day trading on Friday, hitting $37.11. The stock had a trading volume of 402,821 shares. The company’s market cap is $1.98 billion. The firm’s 50 day moving average price is $38.25 and its 200-day moving average price is $34.82. Theravance Biopharma has a one year low of $21.97 and a one year high of $43.44.
Theravance Biopharma (NASDAQ:TBPH) last released its quarterly earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($1.27) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.14) by $0.13. Theravance Biopharma had a negative net margin of 641.67% and a negative return on equity of 67.69%. The firm had revenue of $3.09 million for the quarter, compared to the consensus estimate of $5.07 million. On average, equities research analysts anticipate that Theravance Biopharma will post ($4.64) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Theravance Biopharma, Inc. (TBPH) Downgraded by BidaskClub” was first published by American Banking News and is owned by of American Banking News. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.americanbankingnews.com/2017/07/16/theravance-biopharma-inc-tbph-downgraded-by-bidaskclub.html.
Several large investors have recently added to or reduced their stakes in TBPH. Two Sigma Investments LP boosted its stake in Theravance Biopharma by 153.3% in the fourth quarter. Two Sigma Investments LP now owns 26,931 shares of the biopharmaceutical company’s stock valued at $859,000 after buying an additional 16,299 shares during the last quarter. Harvest Management LLC bought a new stake in Theravance Biopharma during the first quarter valued at $228,000. American Century Companies Inc. bought a new stake in Theravance Biopharma during the first quarter valued at $1,132,000. Teachers Advisors LLC boosted its stake in Theravance Biopharma by 19.2% in the fourth quarter. Teachers Advisors LLC now owns 69,563 shares of the biopharmaceutical company’s stock valued at $2,218,000 after buying an additional 11,201 shares during the last quarter. Finally, State Street Corp boosted its stake in Theravance Biopharma by 18.3% in the fourth quarter. State Street Corp now owns 851,024 shares of the biopharmaceutical company’s stock valued at $27,136,000 after buying an additional 131,646 shares during the last quarter. Institutional investors and hedge funds own 84.30% of the company’s stock.
About Theravance Biopharma
Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.
Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.